Conversely, currently available data indicate that LABA/LAMAs provide a smaller reduction over LABA (10-12%) that does not reach the threshold of clinical relevance.
Indeed, the ICS containing extrafine combination consistently results in a significant reduction of exacerbations over LABA (25-30% on average) which is considered clinically-relevant being anchored to an improvement in patients’ quality of life.
A comparative analysis of published data presented at the American Thoracic Society annual congress in San Francisco (May 13-18) shows that in patients with COPD the fixed combination of the ICS/LABA Beclomethasone/Formoterol (BDP/FF) in an extrafine formulation reduces the frequency of moderate/severe exacerbations more effectively than the combination of LABA/Long-Acting Muscarinic Antagonist (LAMA) in comparison to the corresponding monotherapies. Parma (Italy), – In the treatment of chronic obstructive pulmonary disease (COPD) the combination of inhaled corticosteroids (ICS) and long acting bronchodilators LABA (Long Acting Beta2-agonists) reduces moderate and severe exacerbations, and it is recommended for this purpose in the in-force clinical guidelines.
0 kommentar(er)
